Edgar Filing: MARINUS PHARMACEUTICALS INC - Form 4

MARINUS Form 4 January 19,	PHARMACEUT	ICALS INC							
FORM Check ti if no lo subject Section Form 4 Form 5 obligati may co <i>See</i> Insi 1(b).	this box nger to 16. or Section 17(MENT OF CH rsuant to Sectio (a) of the Public	S SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Section 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Section of the Investment Company Act of 1940				OMB APPROVAL OMB 3235-0287 Number: January 31 Expires: 2005 Estimated average burden hours per response 0.5		
(Print or Type	e Responses)								
1. Name and Address of Reporting Person <u>*</u> Smith Edward F			ssuer Name and T bol RINUS PHAR [[MRNS]		Issuer ALS				
	. ,	(Mor 01/1 0 N	nte of Earliest Tran nth/Day/Year) 7/2017	isaction	Director X Officer (give below)		% Owner ler (specify		
RADNOR	(Street)	4. If Amendment, Date Original Filed(Month/Day/Year)			Applicable Line) _X_ Form filed by C Form filed by M	X Form filed by One Reporting Person Form filed by More than One Reporting			
(City)	(State)	(Zip)	Table I - Non-Dei	rivativa Socurit	Person ies Acquired, Disposed of	or Bonoficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		3. 4. if TransactionA Code D	Securities cquired (A) or isposed of (D) nstr. 3, 4 and 5) (A) or	5. Amount of 6 Securities F Beneficially (I Owned (I Following (I Reported Transaction(s) (Instr. 3 and 4)	. Ownership orm: Direct D) or Indirect	7. Nature of Indirect		
Reminder: Ro	eport on a separate lind	e for each class of	securities benefici	Persons who information of required to re	ctly or indirectly. o respond to the collect contained in this form a espond unless the form urrently valid OMB con	are not n	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	\$ 1.21	01/17/2017		А	58,800	<u>(1)</u>	01/17/2027	Common Stock	58,800
Restricted stock	<u>(2)</u>	01/17/2017		А	25,200	(3)	<u>(4)</u>	Common Stock	25,200

Edgar Filing: MARINUS PHARMACEUTICALS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Smith Edward F C/O MARINUS PHARMACEUTICALS 170 N RADNOR CHESTER RD SUITE 250 RADNOR, PA 19087			CFO		
Signatures					

/s/ Edward F. 01/19/2017 Smith Date **Signature of Reporting Person

Explanation of Responses:

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Options to purchase shares of common stock vest in 36 equal monthly installments commencing 1/31/2017.
- (2) Each share of restricted stock represents the right to receive, at settlement, one share of common stock.
- (3) Shares of restricted stock vest in three equal annual installments of 8,400 on 1/17/18, 1/17/19 and 1/17/20.

(4) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.